Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial-Reference-Cited by-同舟云学术

Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial

Published:2022-07-28 Issue:1 Volume:7 Page:37-46
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Felizzi F.,Launonen Aino^ORCID,Thuresson P.-O.

Funder

F. Hoffmann-La Roche Ltd

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-022-00339-1.pdf

Reference32 articles.

1. NCCN Guidelines Version 3.2020. B-cell Lymphomas. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed 5 Dec 2019.

2. Tilly H, Gomes da Silva M, Vitolo U, et al. ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116–25.

3. Morrison VA, Shou Y, Bell JA, et al. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol. 2019;15:1021–34.

4. Raut LS, Chakrabarti PP. Management of relapsed-refractory diffuse large B cell lymphoma. South Asian J Cancer. 2014;3:66–70.

5. Mehta-Shah N, Bartlett NL. Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood. 2018;131(15):1698–703.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma;Journal of Medical Economics;2023-09-15